Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keya Joshi

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
Journal of Medical Economics|October 31, 2024
The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA Autumn 2024 vaccines in the United KingdomMichele Kohli, Michael Maschio, Amy Lee, et al.
Journal of Medical Economics|February 28, 2026
Modeling the cost-effectiveness of the next-generation COVID-19 mRNA-1283 vaccine in the United StatesKelly Fust, Michele Kohli, Keya Joshi, et al.
Advances in Therapy|June 6, 2026
Comparative Effectiveness of mRNA-1273 Versus Protein-Based NVX-CoV2705 Vaccination on COVID-19-Related Outcomes Among Insured Adults in the United States During 2024-2025: A Retrospective Matched Cohort StudyAmanda Wilson, Ekkehard Beck, Heather Hensler, et al.
Infectious Diseases and Therapy|April 15, 2025
Clinical Impact and Cost-Effectiveness of Updated 2023/24 COVID-19 mRNA Vaccination in High-Risk Populations in the United StatesKeya Joshi, Mariia Dronova, Ewelina Paterak, et al.
Human Vaccines & Immunotherapeutics|November 14, 2024
Substantial reduction in the clinical and economic burden of disease following variant-adapted mRNA COVID-19 vaccines in immunocompromised patients in FranceAmy Lee, Benjamin Davido, Ekkehard Beck, et al.
Journal of Medical Economics|November 14, 2023
The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA fall 2023 vaccines in the United StatesMichele A Kohli, Michael Maschio, Keya Joshi, et al.
Journal of Medical Economics|December 5, 2023
Clinical impact and cost-effectiveness of the updated COVID-19 mRNA Autumn 2023 vaccines in GermanyKeya Joshi, Stefan Scholz, Michael Maschio, et al.
Vaccine|May 15, 2026
The cost-effectiveness of vaccination against COVID-19 in at-risk populations and older adults in the United Kingdom: Projections using a dynamic transmission modelMichele Kohli, Michael Maschio, Amy Lee, et al.
Vaccines|April 27, 2024
The Potential Economic Impact of the Updated COVID-19 mRNA Fall 2023 Vaccines in JapanKelly Fust, Keya Joshi, Ekkehard Beck, et al.
Infectious Diseases and Therapy|January 10, 2026
Evaluating the Effectiveness of 2024-2025 Seasonal mRNA-1273 Vaccination Against COVID-19-Related Hospitalizations and Medically Attended COVID-19 Among Adults Aged ≥ 18 years in the United States: An Observational Matched Cohort StudyNevena Vicic, Alina Bogdanov, Zhe Zheng, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Journal of Medical Economics|October 31, 2024
The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA Autumn 2024 vaccines in the United KingdomMichele Kohli, Michael Maschio, Amy Lee, et al.
Journal of Medical Economics|February 28, 2026
Modeling the cost-effectiveness of the next-generation COVID-19 mRNA-1283 vaccine in the United StatesKelly Fust, Michele Kohli, Keya Joshi, et al.
Advances in Therapy|June 6, 2026
Comparative Effectiveness of mRNA-1273 Versus Protein-Based NVX-CoV2705 Vaccination on COVID-19-Related Outcomes Among Insured Adults in the United States During 2024-2025: A Retrospective Matched Cohort StudyAmanda Wilson, Ekkehard Beck, Heather Hensler, et al.
Infectious Diseases and Therapy|April 15, 2025
Clinical Impact and Cost-Effectiveness of Updated 2023/24 COVID-19 mRNA Vaccination in High-Risk Populations in the United StatesKeya Joshi, Mariia Dronova, Ewelina Paterak, et al.
Human Vaccines & Immunotherapeutics|November 14, 2024
Substantial reduction in the clinical and economic burden of disease following variant-adapted mRNA COVID-19 vaccines in immunocompromised patients in FranceAmy Lee, Benjamin Davido, Ekkehard Beck, et al.
Journal of Medical Economics|November 14, 2023
The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA fall 2023 vaccines in the United StatesMichele A Kohli, Michael Maschio, Keya Joshi, et al.
Journal of Medical Economics|December 5, 2023
Clinical impact and cost-effectiveness of the updated COVID-19 mRNA Autumn 2023 vaccines in GermanyKeya Joshi, Stefan Scholz, Michael Maschio, et al.
Vaccine|May 15, 2026
The cost-effectiveness of vaccination against COVID-19 in at-risk populations and older adults in the United Kingdom: Projections using a dynamic transmission modelMichele Kohli, Michael Maschio, Amy Lee, et al.
Vaccines|April 27, 2024
The Potential Economic Impact of the Updated COVID-19 mRNA Fall 2023 Vaccines in JapanKelly Fust, Keya Joshi, Ekkehard Beck, et al.
Infectious Diseases and Therapy|January 10, 2026
Evaluating the Effectiveness of 2024-2025 Seasonal mRNA-1273 Vaccination Against COVID-19-Related Hospitalizations and Medically Attended COVID-19 Among Adults Aged ≥ 18 years in the United States: An Observational Matched Cohort StudyNevena Vicic, Alina Bogdanov, Zhe Zheng, et al.
Pageof 4